Tumour Registry Lung Cancer (TLK)

Lung Cancer Clinical Trial

Official title:

Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01192919
• Other study ID #: IOM TLK
• Status: Completed
• Start date: January 2010
• Est. completion date: July 2016

Study information

• Verified date: February 2020
• Source: iOMEDICO AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

Description:

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2500
• Est. completion date: July 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy

• written informed consent

• start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent

Exclusion Criteria:

• patients not receiving any systemic therapy

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
iOMEDICO AG

References & Publications (2)

Steffens CC, Elender C, Hutzschenreuter U, Dille S, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - — View Citation

von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, Jänicke M, Marschner N; TLK-Group (Tumour Registry Lung Cancer). Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Documentation of actually used therapy forms in bronchial carcinoma requiring treatment		3 years per patient